Met Life Investment Management, LLC Erasca, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 103,686 shares of ERAS stock, worth $264,399. This represents 0.0% of its overall portfolio holdings.
Number of Shares
103,686
Previous 68,331
51.74%
Holding current value
$264,399
Previous $161,000
75.78%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ERAS
# of Institutions
140Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$49.4 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$42.9 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$41.4 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$35.1 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$33.9 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $311M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...